PMV Pharmaceuticals Completes $50 Million Offering, Extending Expected Funding Into 2028
Research spending fell, while warrant-related charges widened the quarterly loss ahead of a planned ovarian cancer approval application.
PMV Pharmaceuticals, which is developing the cancer pill rezatapopt, completed a $50 million offering that it expects to fund operations into the first quarter of 2028. Its Tuesday earnings release put cash and investments at $108.5 million at September’s end, with an ovarian cancer approval application planned for the first quarter of 2027.
Funding The Rezatapopt Application
PMV’s cash and investments compared with $112.9 million at the end of 2025. It used $52.4 million of cash in operations during the first nine months of 2026, versus $56.4 million in the same period a year earlier.
The company has no approved products to sell. Rezatapopt is designed to restore the cancer-suppressing function of p53 when the protein carries the Y220C mutation. PMV retains worldwide commercial rights to its programs and uses outside manufacturers to produce its drug candidates.
PMV President and CEO David Mack tied the financing to the next regulatory step: “The completed $50 million public offering also positions us well to submit an NDA in the first quarter of 2027 seeking accelerated approval for treatment of platinum-resistant/refractory ovarian cancer patients with a TP53 Y220C mutation.”
Warrant Charges Widened The Loss
PMV lost $34.4 million in the third quarter, versus $21.1 million a year earlier, with a $12.8 million non-cash charge from revaluing stock warrants and $2.3 million of warrant-related offering costs. The company attributed the wider loss primarily to those financing-related expenses, partly offset by lower outside research costs.
Research spending fell to $16.1 million from $18.2 million a year earlier. PMV attributed that decrease chiefly to lower costs from outside research organizations working on rezatapopt. Administrative expenses declined to $4.0 million from $4.3 million; the company credited lower finance and legal support costs, partly offset by increased personnel expenses.
The operating loss narrowed to $20.1 million from $22.5 million. The net loss per share widened to $0.52 from $0.40.
Ovarian Cancer Data Comes Next
The clinical backdrop is the interim ovarian cancer update PMV announced on August 31. Investigators reported a 46% response rate among 76 evaluable patients, using a May 14, 2026 data cutoff. Confirmed responses lasted a median of 10.0 months, and the median time to response was 1.3 months.
Enrollment for the ovarian cancer primary analysis is complete. The trial also evaluates rezatapopt in lung, breast and endometrial cancers and other solid tumors. PMV plans to present updated trial results on November 20 at ENA 2026, including the ovarian cancer primary analysis population and the other tumor groups.
“The updated monotherapy interim data demonstrate the potential for rezatapopt to address a significant unmet medical need,” Mack said.
PMV also reported appointing Philip Herman as chief commercial officer and Matt Eckler of Samsara BioCapital to its board.
PMV plans to seek accelerated FDA approval for ovarian cancer that resists platinum-based treatment or does not respond to it, in patients whose tumors carry the TP53 Y220C mutation.
Sources
- 8-K Filing — PMV Pharmaceuticals, Inc. (PMVP) — SEC EDGAR
- Exhibit pmvp-ex99_1.htm — PMV Pharmaceuticals, Inc. 8-K exhibit — SEC EDGAR
- Pivotal Phase 2 Rezatapopt PYNNACLE Data to Be Featured in — globenewswire.com
- 8-K filed 2026-08-31 — PMV Pharmaceuticals, Inc. (earlier disclosure) — SEC EDGAR